I don't know what you guys have against TTF. My attitude with it is the same as with DCVax-L: issues with the clinical trials, benefit that is arguably marginal because of the conduct of the pivotal trial, and challenges with delivering to patients.
It is the one success that this field has had since temozolomide itself. You should be holding it up as a key example of the benchmark that needs to be achieved (which DCVax-L appeared to clear with its own phase 3 trial, except for not having a "true placebo").
Market Data 
Markets 
AI
